Filters

APOD Antibody

APOD Antibody size: 0.1ml 263

Price 263
Size 0.1ml
Long nameAPOD Primary Polyclonal Antibody
Also known asAPOD PAb
CategoryPrimary Antibodies
ConjugationUnconjugated
Target AntigenAPOD
SpecificityThis is a highly specific antibody against APOD
Modification(s)None
Modification site(s)Unmodified antibody
ClonalityPolyclonal antibody
Clone numberPolyclonal antibody
Concentration1ug per 1ul
Immunogen range20-70/189
Subcellular locationSecreted
SourceThis antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human APOD
Gene ID number347
Swiss ProtP05090
Tested Applications IF(IHC-P), IHC-P, WB
Recommended dilutions IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000)
Cross reactivity Mouse, Rat, Human
Cross reactive species details not every possible cross-reactivity is known, Due to limited amount of testing and knowledge
Background of the target antigen Appears to be able to transport a variety of ligands in a number of different contexts, It is probably involved in the transport and binding of bilin, APOD occurs in the macromolecular complex with lecithin-cholesterol acyltransferase
Purification methodThis antibody was purified via Protein A
Storage conditions 50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA
Synonym names Apo-D, ApoD, Apolipoprotein D
PropertiesC, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24°
Gene targetAPOD
Short nameAPOD Antibody
Technique antibodies against human proteins, antibodies for, Antibody
Alternative nameAPOD (Antibody to)
Alternative techniqueantibodies
Identity 612
Gene APOD
Long gene name apolipoprotein D
Locus 3q29
Discovery year 2001-06-22
Entrez gene record 347
Pubmed identfication 2439269 3453108
RefSeq identity NM_001647
Classification Apolipoproteins Lipocalins
Havana BLAST/BLAT OTTHUMG00000155854

Subscribe to our Newsletter